Agus, David B. 1965-
Agus, David, 1965-
David Agus American physician
Agus, David B.
David Agus
אגוס, דייוויד, 1965-
Agus, David
VIAF ID: 187540353 (Personal)
Permalink: http://viaf.org/viaf/187540353
Preferred Forms
- 200 _ | ‡a Agus ‡b David B. ‡f 1965-....
- 100 1 _ ‡a Agus, David
-
-
-
- 100 1 _ ‡a Agus, David B. ‡d 1965-
-
- 100 1 _ ‡a Agus, David B., ‡d 1965-
-
- 100 1 _ ‡a Agus, David B., ‡d 1965-....
- 100 1 _ ‡a Agus, David B. ‡d 1965-
- 100 1 _ ‡a Agus, David ‡d 1965-
- 100 1 _ ‡a Agus, David, ‡d 1965-
-
-
-
-
-
-
-
- 100 0 _ ‡a David Agus
- 100 0 _ ‡a David Agus ‡c American physician
-
4xx's: Alternate Name Forms (38)
5xx's: Related Names (1)
- 551 _ _ ‡a Baltimore, Md.
Works
Title | Sources |
---|---|
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts | |
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth | |
Applications of Proteomics in Prostate Cancer | |
Body image predicts quality of life in men with prostate cancer | |
The book of animal secrets : nature's lessons for a long and happy life | |
breve guia para uma vida longa | |
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors | |
The current state of preclinical prostate cancer animal models | |
David Agus: Eine neue Strategie im Kampf gegen den Krebs | |
David Agus: Kansere karşı savaşta yeni bir strateji | |
David Agus: Una nueva estrategia en la guerra contra el cáncer. | |
Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains | |
Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke | |
Ductal adenocarcinoma of the prostate | |
Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. | |
einfache Weg zu einem langen Leben | |
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group | |
End of illness | |
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. | |
Epithelial membrane protein-1 is a biomarker of gefitinib resistance. | |
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer | |
fim da doença uma visão revolucionária da saúde e da qualidade de vida | |
El Fin de la enfermedad | |
La fin de la maladie, et si c'était possible ? | |
Genki de nagaiki suru tame no totemo kantan na shukan. | |
Gesundheit auf Bestellung so profitieren Sie gezielt von den Segnungen der modernen Medizin | |
Hábitos prodigiosos para vivir más y mejor | |
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer | |
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation | |
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells | |
Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma | |
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma | |
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase | |
Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. | |
Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). | |
Ji endo obu irunesu : Byoki ni naranai ikikata. | |
JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines | |
En kort guide til et langt liv | |
Kraj bolesti | |
Krátký průvodce pro dlouhý život : [jak si dlouhodobě a snadno udržovat pevné zdraví] | |
Leben ohne Krankheit | |
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. | |
lucky years | |
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) | |
MultiCellDS: a standard and a community for sharing multicellular data | |
Multiparameter computational modeling of tumor invasion | |
n2011065193 | |
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes | |
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer | |
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | |
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium | |
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th | |
A physical sciences network characterization of non-tumorigenic and metastatic cells | |
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal | |
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments | |
Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping | |
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence | |
ProteoWizard: open source software for rapid proteomics tools development | |
Quantifying differences in cell line population dynamics using CellPD. | |
Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition | |
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. | |
Recent developments and future directions with HER-2 in breast cancer and other tumor types | |
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models | |
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). | |
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. | |
Short guide to a long life | |
Single cell dynamic phenotyping | |
Stromal cell oxidation: a mechanism by which tumors obtain vitamin C | |
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo | |
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. | |
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | |
Targeting the HER-kinase axis in cancer | |
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells | |
Update on HER-kinase-directed therapy in prostate cancer. | |
A vida sem doenças | |
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters | |
Дэвид Агус: Новая стратегия в борьбе с раком | |
המדריך הקצר לחיים ארוכים | |
הקץ למחלות | |
나를 살리는 건강습관 65 | |
데이빗 아구스: 암과의 전쟁에 있어서 새로운 전략 | |
질병의 종말 건강과 질병에 대한 새로운 통찰 | |
ジエンド・オブ・イルネス : 病気にならない生き方 | |
デイビット・アガス: がんとの戦いへの新しい戦略 | |
元気で長生きするための、とても簡単な習慣 | |
抗癌斗争的新策略 |